Targets to Therapies: Aggregation and Synuclein Biology Target Validation
Funds research to validate aggregation and synuclein biology targets in Parkinson’s disease, aiming to advance understanding and accelerate new therapeutic development.
Funder: Michael J. Fox Foundation for Parkinson's Research
Due Dates: No fixed deadline (rolling submissions)
Funding Amounts: Award size and duration vary by project; funding is milestone-driven and tailored to the needs of each target validation effort.
Summary: Supports research to validate aggregation and synuclein biology targets relevant to Parkinson's disease, advancing them toward therapeutic development.
Key Information: Open Science Policy applies: all research outputs must be shared openly and promptly.
Description
This funding opportunity from the Michael J. Fox Foundation for Parkinson's Research supports projects that strengthen the scientific foundation for aggregation and synuclein biology targets with high relevance to Parkinson’s disease. The program is designed to clarify the human significance of these targets, define their mechanisms in Parkinson’s-related contexts, establish target engagement, and develop necessary tools and assays. The ultimate goal is to generate robust, reproducible, and translatable data that can move promising targets toward therapeutic decision points and accelerate the development of new treatments for Parkinson’s disease.
